Trump Highlights Ozempic Price Gap at White House Dinner
Trump Highlights Ozempic Price Gap at White House Dinner
Anonymous
Key Points
1
In an earlier version of the anecdote, Trump described the man as “highly neurotic,” “seriously overweight,” and a “fat shot drug” taker when he was promoting an Ozempic-price initiative tied to May 2025 executive-order action.
2
Newsweek reports Trump first told the London-vs.-New York Ozempic pricing story after signing an executive order directing his administration to pursue “most-favored-nation pricing” for medicines.
3
TrumpRx’s disclosed pricing target is more specific than described in the summary: the program is described as dropping prices of Ozempic (and fellow GLP-1 drugs Wegovy and Zepbound) to between $199 and $350 per month.
4
LehighValleyLive says Trump told the audience the exchange “got me going,” describing it as part of his agreement with Ozempic’s manufacturer to lower costs in the U.S. through TrumpRx.
President Donald Trump retold a story at a White House Rose Garden dinner in which he mocked an unnamed Wall Street financier over his weight and the cost of Ozempic. According to Newsweek, Trump described the man as complaining about a stark pricing gap: $86 for the drug in London versus roughly $1,300 in New York, despite both coming from the same source. Trump said he told the man the medication "isn't working" and remarked, "you look like shit."
The president tied the anecdote to his TrumpRx program, which aims to lower U.S. prices for weight-loss drugs like Ozempic, Wegovy, and Zepbound to between $199 and $350 per month. RadarOnline reports the remarks drew swift criticism for mocking the man's weight and raising questions about Trump's temperament. The story underscores Trump's broader push for "most-favored-nation pricing" — a policy designed to match lower overseas drug costs.
The $1,200 Price Gap Sparks Drug Policy Talk
The London-to-New York pricing disparity Trump describes is real and troubling. Newsweek reports Trump first told this anecdote after signing an executive order directing his administration to pursue lower medicine prices through "most-favored-nation" agreements. The same Ozempic dose costs 93% less in London. This gap — in theory from the same factory — illustrates why U.S. patients often pay far more than their global peers for identical drugs.
TrumpRx Targets Three Major Weight-Loss Drugs
Trump's TrumpRx initiative sets a clear price ceiling. RadarOnline reports the program aims to cut monthly costs for Ozempic, Wegovy, and Zepbound to between $199 and $350. That's a 75% to 85% reduction from the $1,300 figure Trump cited. The goal is to negotiate directly with manufacturers, similar to how Medicare does with other drugs. Whether these negotiations will succeed remains unclear — Ozempic's maker has not yet agreed to the full price drop Trump claims.
Critics Question Trump's Tone and Judgment
The way Trump delivered the story triggered widespread backlash. AOL reports he repeatedly called Ozempic a "fat drug" and emphasized the man's weight rather than the policy substance. Some observers questioned whether mocking a person's body and health choices is appropriate for a president, even in jest. Others noted the repeated telling of a supposedly private conversation — the man allegedly "begged" Trump not to name him — raises questions about discretion and respect for privacy.
The tone also risks undermining the policy message. By framing GLP-1 drugs primarily through mockery and weight stigma, rather than medical effectiveness or affordability alone, Trump may affect public trust in the reform itself. TheMirror notes critics worry the remarks signal a lack of focus on the serious issue of drug pricing and instead emphasize personal insult. Health-policy experts say this approach can discourage people from seeking weight-loss treatment due to shame — the opposite of most public-health goals.
Sentiment
Mostly NegativeNEGATIVENEUTRALPOSITIVE
Publishers
12
Articles
14
Reach
26
A
AnonymousAuthor
